Vivos Therapeutics (NASDAQ:VVOS) Releases Earnings Results, Beats Estimates By $0.01 EPS

Vivos Therapeutics (NASDAQ:VVOS) released its quarterly earnings data on Wednesday. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.01, FiscalAI reports. Vivos Therapeutics had a negative net margin of 99.49% and a negative return on equity of 232.76%. The company had revenue of $6.78 million for the quarter, compared to analyst estimates of $4.49 million.

Vivos Therapeutics Stock Performance

VVOS traded down $0.11 during trading on Wednesday, hitting $2.36. The stock had a trading volume of 62,825 shares, compared to its average volume of 360,140. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.05 and a quick ratio of 1.05. The company has a 50 day moving average price of $2.97 and a 200-day moving average price of $3.52. Vivos Therapeutics has a one year low of $1.98 and a one year high of $7.95. The firm has a market cap of $17.71 million, a price-to-earnings ratio of -1.40 and a beta of 6.88.

Wall Street Analyst Weigh In

VVOS has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Wednesday, October 8th. Zacks Research downgraded Vivos Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, October 31st. Wall Street Zen lowered Vivos Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 10th. Ascendiant Capital Markets raised their price target on Vivos Therapeutics from $6.20 to $6.50 and gave the company a “buy” rating in a report on Tuesday, September 9th. Finally, HC Wainwright started coverage on shares of Vivos Therapeutics in a research report on Monday. They set a “buy” rating and a $7.00 price objective for the company. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Vivos Therapeutics currently has an average rating of “Hold” and an average price target of $5.25.

Institutional Investors Weigh In On Vivos Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of Vivos Therapeutics in the second quarter valued at about $65,000. B. Riley Wealth Advisors Inc. bought a new stake in Vivos Therapeutics in the 2nd quarter valued at about $220,000. Finally, Connective Capital Management LLC acquired a new position in shares of Vivos Therapeutics during the 3rd quarter worth approximately $620,000. Institutional investors and hedge funds own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.